These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 26114862

  • 1. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
    Benter IF, Sarkhou F, Al-Khaldi AT, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Akhtar S.
    J Drug Target; 2015; 23(6):506-18. PubMed ID: 26114862
    [Abstract] [Full Text] [Related]

  • 2. Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction.
    Akhtar S, Yousif MH, Dhaunsi GS, Sarkhouh F, Chandrasekhar B, Attur S, Benter IF.
    PLoS One; 2013; 8(6):e67813. PubMed ID: 23826343
    [Abstract] [Full Text] [Related]

  • 3. Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor.
    Akhtar S, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH, Benter IF.
    PLoS One; 2015; 10(11):e0141657. PubMed ID: 26536590
    [Abstract] [Full Text] [Related]

  • 4. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.
    Cancer Res; 2006 Jan 01; 66(1):404-11. PubMed ID: 16397255
    [Abstract] [Full Text] [Related]

  • 5. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.
    Oncogene; 2002 Sep 12; 21(41):6255-63. PubMed ID: 12214266
    [Abstract] [Full Text] [Related]

  • 6. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D.
    Clin Cancer Res; 2010 Feb 15; 16(4):1159-69. PubMed ID: 20145185
    [Abstract] [Full Text] [Related]

  • 7. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.
    Cancer Res; 2008 Jan 15; 68(2):571-9. PubMed ID: 18199554
    [Abstract] [Full Text] [Related]

  • 8. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF, Zhu XF, Zhong GS, Deng BG.
    Dis Esophagus; 2013 Jul 15; 26(5):487-95. PubMed ID: 22458639
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed.
    Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S.
    Br J Pharmacol; 2005 Jul 15; 145(6):829-36. PubMed ID: 15852031
    [Abstract] [Full Text] [Related]

  • 11. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H.
    Oncol Rep; 2012 May 15; 27(5):1639-45. PubMed ID: 22293713
    [Abstract] [Full Text] [Related]

  • 12. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature.
    Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, Akhtar S.
    Vascul Pharmacol; 2009 Oct 15; 51(4):236-45. PubMed ID: 19577003
    [Abstract] [Full Text] [Related]

  • 13. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
    Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.
    Int J Cancer; 2013 Jul 15; 133(1):235-46. PubMed ID: 23292912
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL, Xia W, Spector NL.
    Clin Cancer Res; 2008 Nov 01; 14(21):6730-4. PubMed ID: 18980964
    [Abstract] [Full Text] [Related]

  • 15. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 16. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL.
    Oncogene; 2005 Sep 15; 24(41):6213-21. PubMed ID: 16091755
    [Abstract] [Full Text] [Related]

  • 17. Knockout of vascular smooth muscle EGF receptor in a mouse model prevents obesity-induced vascular dysfunction and renal damage in vivo.
    Stern C, Schreier B, Nolze A, Rabe S, Mildenberger S, Gekle M.
    Diabetologia; 2020 Oct 15; 63(10):2218-2234. PubMed ID: 32548701
    [Abstract] [Full Text] [Related]

  • 18. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY, Bang YJ.
    Cancer Lett; 2008 Dec 18; 272(2):296-306. PubMed ID: 18774637
    [Abstract] [Full Text] [Related]

  • 19. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
    Zhou Y, Brattain MG.
    Cancer Res; 2005 Jul 01; 65(13):5848-56. PubMed ID: 15994962
    [Abstract] [Full Text] [Related]

  • 20. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
    Hasinoff BB, Patel D, Wu X.
    Cardiovasc Toxicol; 2013 Mar 01; 13(1):33-47. PubMed ID: 22948710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.